Cargando…

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV-associated respiratory illness. This recommendat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Homaira, Nusrat, Rawlinson, William, Snelling, Thomas L., Jaffe, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274815/ https://www.ncbi.nlm.nih.gov/pubmed/25548575 http://dx.doi.org/10.1155/2014/571609

Ejemplares similares

Risk factors associated with RSV hospitalisation in the first 2 years of life, among different subgroups of children in NSW: a whole-of-population-based cohort study
por: Homaira, Nusrat, et al.
Publicado: (2016)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Transplacental transfer of RSV antibody in Australian First Nations infants
por: Homaira, Nusrat, et al.
Publicado: (2022)

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children
por: Ambrose, Christopher S, et al.
Publicado: (2014)

Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort study
por: Homaira, Nusrat, et al.
Publicado: (2017)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Impact of influenza on hospitalization rates in children with a range of chronic lung diseases
por: Homaira, Nusrat, et al.
Publicado: (2019)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

Assessment of Variation in Care Following Hospital Discharge for Children with Acute Asthma
por: Chan, Mei, et al.
Publicado: (2021)

Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
por: Stewart, Dan L, et al.
Publicado: (2013)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration
por: Packnett, Elizabeth R., et al.
Publicado: (2023)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Dispensing Practices of Fixed Dose Combination Controller Therapy for Asthma in Australian Children and Adolescents
por: Homaira, Nusrat, et al.
Publicado: (2020)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
por: Mulot, Gwenaelle, et al.
Publicado: (2022)

Is immunization with palivizumab really effective in high-risk children?
por: Raguž, Marjana Jerković, et al.
Publicado: (2023)

Assessing the appropriateness of paediatric antibiotic overuse in Australian children: a population-based sample survey
por: Arnolda, Gaston, et al.
Publicado: (2020)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017
por: Fitzpatrick, Tiffany, et al.
Publicado: (2021)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo
por: Jacobino, Shamir R., et al.
Publicado: (2018)

Asthma and Susceptibility to COVID-19 in Australian Children During Alpha, Delta and Omicron Waves of the COVID-19 Pandemic
por: Chan, Mei, et al.
Publicado: (2023)

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study: Palivizumab prophylaxis in children with congenital heart disease
por: Ratti, Chiara, et al.
Publicado: (2023)

Rate of use and effectiveness of oseltamivir in the treatment of influenza illness in high‐risk populations: A systematic review and meta‐analysis
por: Shim, So‐Jung, et al.
Publicado: (2021)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

2639. Role of Antimicrobial Stewardship Program (ASP) in Monitoring Community Transmission of Respiratory Syncytial Virus (RSV) to Determine Optimal Timing of Inpatient Palivizumab Administration at a Pediatric Hospital
por: Shapiro, Craig, et al.
Publicado: (2023)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
por: Fernández, Pilar, et al.
Publicado: (2010)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
por: Chen, Jinghan Jenny, et al.
Publicado: (2015)

Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis
por: Oncel, Mehmet Yekta, et al.
Publicado: (2013)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
por: Monteiro, Ana Isabel M. P., et al.
Publicado: (2014)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
por: al-Alaiyan, Saleh, et al.
Publicado: (2015)

Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis
por: Anderson, Evan J., et al.
Publicado: (2017)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f3htrh8aqb0jc3m9v7p3hd67tr